Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Chemotherapy and Anlotinib for Recurrent Ovarian Cancer
NCT07286240Phase 2Recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in ovarian cancer, sponsored by Cancer Center of Guangzhou Medical University. Started Nov 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07286240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286240.